Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 7

Integrin alpha 4 beta 7

Brief Information

Name:Integrin alpha-4/beta-7
Target Synonym:LPAM-1,Lymphocyte Peyer s patch Adhesion Molecule 1
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT7-C52W4-SPR
 Integrin alpha 4 beta 7 SPR

Human MAdCAM-1, Fc Tag (Cat. No. MAM-H5253) captured on Protein A Chip can bind Cynomolgus ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-C52W4) with an affinity constant of 5.77 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IT7-H52W4-SPR
 Integrin alpha 4 beta 7 SPR

Anti-Human Integrin α 4 β 7 MAb, Human IgG1 (ADCC Disable) captured on Protein A Chip can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (IT7-H52W4) with an affinity constant of 1.37 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

Integrin alpha 4 beta 7,ITGA4&ITGB7

Background

Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc Entyvio, Entyvio Pen, Kynteles, 安吉优 United States Colitis, Ulcerative; Crohn Disease Takeda Pharmaceuticals USA Inc 2014-05-20 Pediatric ulcerative colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Gastritis; Urogenital Neoplasms; Colitis, Ulcerative; Cholangitis, Sclerosing; Celiac Disease; Solid tumours; Colitis; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; HIV Infections; Hematopoietic stem cell transplantation (HSCT) Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Multiple Sclerosis; Crohn Disease Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Crohn Disease; Multiple Sclerosis Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Myositis, Inclusion Body; Demyelinating Diseases; Ischemic Stroke; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details
Vedolizumab biosimilar (Polpharma Biologics) PB-016 Phase 3 Clinical Polpharma Biologics Sa Pouchitis; Colitis, Ulcerative; Crohn Disease Details
Vedolizumab biosimilar (Alvotech) AVT-16; AVT16 Phase 3 Clinical Alvotech Swiss Ag Immune System Diseases; Colitis, Ulcerative Details
Natalizumab biosimilar (GENERIUM Pharmaceuticals) GNR-093 Phase 3 Clinical Generium Pharmaceuticals Multiple Sclerosis Details
MORF-057 MORF-057 Phase 2 Clinical Morphic Therapeutic Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
PN-10943 PN-10943-A; PN-10943; PN-943 Phase 2 Clinical Protagonist Therapeutics Inc Colitis, Ulcerative Details
GS-1427 GS-1427 Phase 2 Clinical Gilead Sciences Sl Inflammatory Bowel Diseases; Colitis, Ulcerative Details
ABBV-382 ABBV-382 Phase 2 Clinical Abbvie Inc HIV Infections; Crohn Disease Details
PTG-100 PTG-100 Phase 1 Clinical Protagonist Therapeutics Inc Celiac Disease; Colitis, Ulcerative Details
EA-1080 NSHO-101; EA-1080 Phase 1 Clinical Ea Pharma Inflammatory Bowel Diseases Details
SPY-001 SPY001; SPY-001; PR-011; PR011; SPY001-001 Phase 1 Clinical Paragon Therapeutics Inc Inflammatory Bowel Diseases Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message